4-((3-Acetamidophenyl)amino)-N-cyclopropyl-2-((2-fluoro-4-iodophenyl)amino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis PharmaceuticalsSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tafinlar Novartis Pharmaceuticals | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →